

- dopamine beta hydroxylase, tyrosinase, and tyrosine hydroxylase. *Biol Psychiatry* 1995; 37: 533-40
103. Grice DE, Leckman JF, Pauls DL, et al. Linkage disequilibrium between an allele at the dopamine D<sub>4</sub> receptor locus and Tourette syndrome, by the transmission-disequilibrium test. *Am J Hum Genet* 1996; 59: 644-52
104. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. *J Clin Psychopharmacol* 1995; 15 (1 Suppl. 1): 2-3S
105. Boyfield I, Brown TH, Coldwell MC, et al. Design and synthesis of 2-naphthoate esters as selective dopamine D<sub>4</sub> antagonists. *J Med Chem* 1996; 39: 1946-8
106. Dean B, Hayes W. Decreased cortical serotonin 2A receptors in schizophrenia. *Schizophrenia Res* 1996; 21: 133-9
107. Sodhi MS, Murray RM. Future therapies for schizophrenia. *Exp Opin Ther Patents* 1997; 7 (2): 151-65

---

Correspondence and reprints: Dr *Sanobar Shaikh*, Section of Clinical Psychopharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF, England.  
Email: spjush@iop.bpmf.ac.uk

---

#### Erratum

**Vol. 7, No. 6, page 468:** Features and Properties table. In row 9 (Frequency of administration), column 2, the wording should read '... but not within 2h of the first'.

[Palmer KJ, Spencer CM. *Zolmitriptan*. *CNS Drugs* 1997 Jun; 7 (6): 468-78]